December 20, 2006 -- Altus and Genentech will team up to develop drugs for growth hormone deficiency; VaxGen officially forfeited its $887 million antrax contract; Artes Medical priced its delayed IPO at $6; Kosan licensed its motilin agonist program to Pfizer; Orexigen filed for an IPO; Northfield Labs fell when its blood substitute candidate, PolyHeme, failed to meet its Phase III trial endpoints; Panacos Pharma reported disappointing data for its HIV antiviral drug; Janssen received FDA approval of Invega for schizophrenia; Gilead said its cystic fibrosis treatment met its Phase III endpoint; Repros reported noninferiority for Androxal; CollaGenex out-licensed European rights for Oracea; Seattle Genetics began a Phase II trial of a lymphoma drug; Cytokinetics started a Phase II trial of its cancer drug, ispinesib; Hana Biosciences requested a Special Protocol Assessment for a trial of Marqibo; and Dynavax began a Phase III trial of its hepatitis B virus vaccine. The Centient Biotech 200™ fell a modest 6 points to 3946, a loss of .15%. More details...
